Risk Factors Analysis And Treatment Of Lung Cancer Combined With Thromboembolic Disease

Objective: Thrombosis in patients with cancer is closely related to itself.Hypercoagulable constitution and the corresponding anti-tumor therapy of cancerpatients have become the important factors in thrombosis and poor prognosis. Besides,the thromboembolism will increase the difficulty of anti-tumor therapy, and reduce thequality of life and which lead to a poor prognosis. So to explore the causes ofthrombosis and its relationship with cancer to reduce the incidence of thromboembolismand improve the prognosis become an urgent task. In this paper, we investigated99cases of lung cancer combined with thromboembolic disease who had been treated inthe first hospital of Dalian medical university from2004to2013retrospectively. Thepurpose of this article is to discuss the risk factors, clinical manifestations, diagnosisand therapy of lung cancer with thrombosis, which can increase the clinician’sunderstanding of the importance of prevention and treatment in thromboembolicdisease.Methods: We analyzed99cases of lung cancer with thromboembolism as thethrombosis group, which had been treated in the first hospital of Dalian medicaluniversity from2004to2013retrospectively. We gathered other100cases of lungcancer without thromboembolism as the control group. These patients were treatedduring the same period. The main research of this article contain risk factors，clinicalmanifestations, diagnosis and therapy of lung cancer with thromboembolism. We used the software SPSS17.0to analyze the data. We explain the laboratory test results and—other measurement data byx±s and used the method of two independent samples t-testto verify the results. Finally, risk factors of lung cancer with thromboembolism weredone for single, multiple factors regression analysis, which used χ2test and Logisticregression respectively.Result:1.99cases of lung cancer with thromboembolism were collected as thethrombosis group. In this group, there were31(31.3%) cases with pulmonary embolism,32cases（32.3%）with deep vein thrombosis,18cases（18.2%） with pulmonaryembolism and deep vein thrombosis,2cases (2.0%) with upper extremity venousthromboembolism,2cases (2.0%) with internal jugular venous thromboembolism,2cases (2.0%) with supraclavicular vein thrombosis,11cases months with cerebralembolism and1case (1.1%) with peripheral arterial embolism.2. In the thrombosis group, thromboembolism take placed on59cases (59.6%) within3months since their lung cancer was diagnosed,17cases (17.2%) in3-6months,14cases (14.1%) in6-12months and9cases (9.1%) more than12months.3.The patients whose clinical stage is Ⅲ-Ⅳ has a higher proportion ofthromboembolism，as well as the patients who accepted chemotherapy over4cycles.4The comparison of the two groups with the red blood cell count(RBC), hemoglobinvalue (HGb), Prothrombin time (PT), Prothrombin international normalized ratio (INR)in the thrombosis group were lower than those of control group. The differences werestatistically significant (p<0.05).5. In the thrombosis group,72cases (72.7%) of anticoagulant therapy was effective,15cases (15.2%) was ineffective,12cases (12.1%) did not undergo anticoagulanttherapy.65cases (74.71%) symptoms were relieved within5days, after anticoagulanttherapy.6. Lung cancer with thromboembolism in blood transfusion therapy, chemotherapy,surgery, existed difference (p<0.05). Blood transfusion therapy, chemotherapy andsurgery could be used as the related risk factors for thromboembolism.Conclusion:1. Pulmonary embolism and deep vein thrombosis are common types of lung cancer combined with thromboembolism. The incidence of thromboembolism takeplaced within3months was the highest since the lung cancer was diagnosed.2. Bloodtransfusion therapy, chemotherapy and surgery can be used as related risk factors ofthrombosis.3.Early aggressive anticoagulation, thrombolysis and improvingmicrocirculation are the primary method of improving the treatment efficiency.